Literature DB >> 22513347

Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII.

Lachlan J Smith1, Guilherme Baldo, Susan Wu, Yuli Liu, Michael P Whyte, Roberto Giugliani, Dawn M Elliott, Mark E Haskins, Katherine P Ponder.   

Abstract

Mucopolysaccharidosis type VII (MPS VII) is characterized by deficient β-glucuronidase (GUSB) activity, which leads to accumulation of chondroitin, heparan and dermatan sulfate glycosaminoglycans (GAGs), and multisystemic disease. MPS VII patients can develop kypho-scoliotic deformity and spinal cord compression due to disease of intervertebral disks, vertebral bodies, and associated tissues. We have previously demonstrated in MPS VII dogs that intervertebral disks degenerate, vertebral bodies have irregular surfaces, and vertebral body epiphyses have reduced calcification, but the pathophysiological mechanisms underlying these changes are unclear. We hypothesized that some of these manifestations could be due to upregulation of destructive proteases, possibly via the binding of GAGs to Toll-like receptor 4 (TLR4), as has been proposed for other tissues in MPS models. In this study, the annulus fibrosus of the intervertebral disk of 6-month-old MPS VII dogs had cathepsin B and K activities that were 117- and 2-fold normal, respectively, which were associated with elevations in mRNA levels for these cathepsins as well as TLR4. The epiphyses of MPS VII dogs had a marked elevation in mRNA for the cartilage-associated gene collagen II, consistent with a developmental delay in the conversion of the cartilage to bone in this region. The spine obtained at autopsy from a young man with MPS VII exhibited similar increased cartilage in the vertebral bodies adjacent to the end plates, disorganization of the intervertebral disks, and irregular vertebral end plate morphology. These data suggest that the pathogenesis of destructive changes in the spine in MPS VII may involve upregulation of cathepsins. Inhibition of destructive proteases, such as cathepsins, might reduce spine disease in patients with MPS VII or related disorders.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513347      PMCID: PMC3428127          DOI: 10.1016/j.ymgme.2012.03.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  42 in total

1.  Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.

Authors:  Geoffrey B Johnson; Gregory J Brunn; Yuzo Kodaira; Jeffrey L Platt
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

Review 2.  Mammalian toll-like receptors: from endogenous ligands to tissue regeneration.

Authors:  Z Zhang; H J Schluesener
Journal:  Cell Mol Life Sci       Date:  2006-12       Impact factor: 9.261

3.  Cloning of the canine beta-glucuronidase cDNA, mutation identification in canine MPS VII, and retroviral vector-mediated correction of MPS VII cells.

Authors:  J Ray; A Bouvet; C DeSanto; J C Fyfe; D Xu; J H Wolfe; G D Aguirre; D F Patterson; M E Haskins; P S Henthorn
Journal:  Genomics       Date:  1998-03-01       Impact factor: 5.736

4.  Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.

Authors:  Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

Review 5.  A clear and present danger: endogenous ligands of Toll-like receptors.

Authors:  Jacob A Sloane; Daina Blitz; Zachary Margolin; Timothy Vartanian
Journal:  Neuromolecular Med       Date:  2009-10-14       Impact factor: 3.843

6.  Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation.

Authors:  Wu-Shiun Hou; Zhenqiang Li; Frank H Büttner; Eckart Bartnik; Dieter Brömme
Journal:  Biol Chem       Date:  2003-06       Impact factor: 3.915

7.  Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis.

Authors:  E Solau-Gervais; F Zerimech; R Lemaire; C Fontaine; G Huet; R-M Flipo
Journal:  Scand J Rheumatol       Date:  2007 Sep-Oct       Impact factor: 3.641

8.  Mucopolysaccharidosis type VII (beta-glucuronidase deficiency): a chronic variant with an oligosymptomatic severe skeletal dysplasia.

Authors:  R D de Kremer; I Givogri; C E Argaraña; E Hliba; R Conci; C D Boldini; A P Capra
Journal:  Am J Med Genet       Date:  1992-09-15

9.  Regulation of collagenase activities of human cathepsins by glycosaminoglycans.

Authors:  Zhenqiang Li; Yoshiyuki Yasuda; Weijie Li; Matthew Bogyo; Norman Katz; Ronald E Gordon; Gregg B Fields; Dieter Brömme
Journal:  J Biol Chem       Date:  2003-11-26       Impact factor: 5.157

10.  Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice.

Authors:  Jérôme Ausseil; Nathalie Desmaris; Stéphanie Bigou; Ruben Attali; Sébastien Corbineau; Sandrine Vitry; Mathieu Parent; David Cheillan; Maria Fuller; Irène Maire; Marie-Thérèse Vanier; Jean-Michel Heard
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

View more
  14 in total

1.  Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs.

Authors:  Sun H Peck; Philip J M O'Donnell; Jennifer L Kang; Neil R Malhotra; George R Dodge; Maurizio Pacifici; Eileen M Shore; Mark E Haskins; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2015-09-26       Impact factor: 4.797

2.  The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade.

Authors:  Elizabeth M Xing; Van W Knox; Patricia A O'Donnell; Tracey Sikura; Yuli Liu; Susan Wu; Margret L Casal; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

3.  Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII.

Authors:  Sun H Peck; John W Tobias; Eileen M Shore; Neil R Malhotra; Mark E Haskins; Margret L Casal; Lachlan J Smith
Journal:  Bone       Date:  2019-08-20       Impact factor: 4.398

4.  The effect of Tlr4 and/or C3 deficiency and of neonatal gene therapy on skeletal disease in mucopolysaccharidosis VII mice.

Authors:  Elizabeth M Xing; Susan Wu; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2014-12-19       Impact factor: 4.797

Review 5.  Mucopolysaccharidoses: overview of neuroimaging manifestations.

Authors:  Manal Nicolas-Jilwan; Moeenaldeen AlSayed
Journal:  Pediatr Radiol       Date:  2018-05-11

6.  Evaluation of spinal involvement in children with mucopolysaccharidosis VI: the role of MRI.

Authors:  Elif Bulut; Emine Pektas; Hatice S Sivri; Burcak Bilginer; Mumtaz M Umaroglu; Burce Ozgen
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

7.  Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.

Authors:  Joseph A Chiaro; Patricia O'Donnell; Eileen M Shore; Neil R Malhotra; Katherine P Ponder; Mark E Haskins; Lachlan J Smith
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

Review 8.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

9.  Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs.

Authors:  Joseph A Chiaro; Matthew D Baron; Chelsea M Del Alcazar; Patricia O'Donnell; Eileen M Shore; Dawn M Elliott; Katherine P Ponder; Mark E Haskins; Lachlan J Smith
Journal:  Bone       Date:  2013-04-04       Impact factor: 4.398

Review 10.  Failures of Endochondral Ossification in the Mucopolysaccharidoses.

Authors:  Zhirui Jiang; Sharon Byers; Margret L Casal; Lachlan J Smith
Journal:  Curr Osteoporos Rep       Date:  2020-10-16       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.